MedTrace Logo

Atrial Fibrillation: Canadian Atrial Fibrillation Evaluation (CAFE) Study -

NCT00848445 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2021-05-12

No results posted yet for this study

Summary

To evaluate whether atrial fibrillation (AF) therapies in Guidant Pulsar Max II or Insignia Plus DR have an effect on the occurance of AF in patients with no prior history of AF

Conditions

Interventions

DEVICE

Guidant Pulsar Max II or Insignia Plus DR

market approved pacemaker. programmed per protocol

DEVICE

Atrial pacing preference turned on or off

programing changes in the device

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Lawrence Sterns, MD · Victoria Cardiac Arrythmia trials

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Primary Completion
2007-11-30
Completion
2007-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00848445 on ClinicalTrials.gov